Sarepta Therapeutics (NASDAQ:SRPT) Given New $179.00 Price Target at Mizuho

Sarepta Therapeutics (NASDAQ:SRPT) had its price target increased by Mizuho from $145.00 to $179.00 in a research note issued to investors on Friday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other brokerages have also commented on SRPT. UBS Group upped their price objective on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a buy rating in a research report on Friday, March 1st. Wedbush reaffirmed an outperform rating and set a $224.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Citigroup increased their price target on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a buy rating in a research report on Thursday, February 29th. Needham & Company LLC reissued a buy rating and issued a $166.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, May 2nd. Finally, Evercore ISI increased their price target on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the stock an in-line rating in a research report on Tuesday, February 20th. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of Moderate Buy and an average target price of $163.94.

Sarepta Therapeutics Stock Down 1.0 %

Shares of Sarepta Therapeutics stock traded down $1.36 on Friday, hitting $131.38. 849,008 shares of the company traded hands, compared to its average volume of 1,166,466. The company has a 50-day moving average price of $126.50 and a 200 day moving average price of $112.30. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. Sarepta Therapeutics has a 12-month low of $55.25 and a 12-month high of $152.21. The company has a market cap of $12.42 billion, a PE ratio of 1,194.36 and a beta of 0.95.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm had revenue of $413.50 million during the quarter, compared to analysts’ expectations of $375.52 million. During the same period in the prior year, the company posted ($1.44) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 63.1% on a year-over-year basis. Sell-side analysts predict that Sarepta Therapeutics will post 2.68 earnings per share for the current year.

Insiders Place Their Bets

In other Sarepta Therapeutics news, insider Dallan Murray sold 3,635 shares of the stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the sale, the insider now directly owns 18,125 shares in the company, valued at $2,537,500. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO Ian Michael Estepan sold 1,200 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $128.30, for a total transaction of $153,960.00. Following the sale, the chief financial officer now directly owns 39,114 shares in the company, valued at $5,018,326.20. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Dallan Murray sold 3,635 shares of Sarepta Therapeutics stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total transaction of $508,900.00. Following the completion of the sale, the insider now owns 18,125 shares in the company, valued at $2,537,500. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,731 shares of company stock worth $3,248,319. Company insiders own 7.70% of the company’s stock.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Securities Inc. bought a new stake in shares of Sarepta Therapeutics in the 4th quarter valued at $26,000. Mather Group LLC. acquired a new position in Sarepta Therapeutics during the first quarter worth $28,000. Riggs Asset Managment Co. Inc. raised its holdings in Sarepta Therapeutics by 125.0% during the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares during the last quarter. Montag A & Associates Inc. acquired a new position in Sarepta Therapeutics during the third quarter worth $30,000. Finally, Cary Street Partners Investment Advisory LLC raised its holdings in Sarepta Therapeutics by 154.0% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after buying an additional 154 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.